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Introduction 
Non-Hodgkin’s lymphomas are a heterogeneous group of 
lymphoproliferative malignancies with different behaviour 
patterns, prognosis and management. 
Non-Hodgkin’s lymphoma involves the thoracic struc- 
tures, particularly the mediastinum and lung parenchyma, 
in up to 43% of patients at some stage in the course of 
their disease (1). Endobronchial involvement, however, is 
extremely rare, even in the presence of advanced disease. 
The first report of endobronchial non-Hodgkin’s lym- 
phoma was made by Dawe in 1955 (2). Since this time 
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less than 50 cases have been described in the literature 
(3-6). 
We report a further case and review the relevant literature. 
Case Report 
A 56-year-old man presented with a 3 months’ history of 
dyspnoea and productive cough. He had experienced 5 kg 
weight loss in the preceding year, mild night sweats, but no 
associated fevers. He had a 40 pack-year smoking history. 
The chest radiograph showed consolidation at the right 
lower and middle lobes with widened mediastinum sugges- 
tive of lymphadenopathy (Plate 1). Computed tomography 
(CT) scan of the chest demonstrated extensive mediastinal 
and right hilar lymphadenopathy, distal parenchymal con- 
solidation in the right lower lobe and a large right basal 
pleural fluid collection. 
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PLATE 1. Chest radiograph on presentation showing 
consolidation in right lower and middle lobes, and 
widened mediastinum. 
At fibre-optic bronchoscopy a globular tumour in the 
bronchus intermedius was partially obstructing the right 
middle and lower lobe bronchi. 
Biopsies of the endobronchial tumour revealed atypical 
cells with a diffuse infiltrating pattern. The cells were LCA 
positive with a predominant B-cell phenotype and highly 
suggestive of lymphoma. Axillary lymph node biopsy con- 
firmed the diagnosis of malignant lymphoma, large cell 
type, predominantly follicular but with diffuse areas. 
Bone marrow biopsy showed diffuse involvement by 
lymphoma. Serum LDH was significantly elevated at 
406 U 1 - ’ (normal range 66188 U 1 - ‘), serum calcium 
2.62 mmol 1~ ’ (normal range 2.05-2.55 mmol 1 - ‘) and 
ESR 76 mm h- i. The patient therefore had stage IVA 
follicular large cell non-Hodgkin’s lymphoma. His clinical 
features at presentation placed him in the high-intermediate 
group of the age-adjusted international prognostic index, 
with a predicted 5 year survival of 53% (7). 
Chemotherapy was commenced with cyclophosphamide, 
doxorubian, vincristine and prednisone (CHOP). After the 
first cycle of chemotherapy the patient’s dyspnoea and 
cough had improved dramatically. The patient has com- 
pleted six cycles of CHOP chemotherapy; reassessment 
shows clearing of his bone marrow disease and resolution 
of the thoracic involvement, apart from a residual 1.5 cm 
mediastinal lymph node. 
Discussion 
The presentation of lymphoma with endobronchial involve- 
ment is rare. Moolten described two cases of Hodgkin’s 
disease involving the airways in 1934 (8). Dawe first 
described a case of endobronchial non-Hodgkin’s lym- 
phoma in 1955 (2). Since this time only isolated cases have 
been reported, supporting the impression that such lesions 
are uncommon. 
Vieta and Crower reported the autopsy findings in 55 
cases of non-Hodgkin’s lymphoma. No endobronchial 
involvement was noted in these cases (9). A similar 
necropsy study by Papaioannau and Watson found only 
one endobronchial lesion among 93 cases of primary pul- 
monary lymphoma ( 10). 
In non-Hodgkin’s lymphoma, endobronchial lesions are 
most frequently seen in the main bronchi followed by the 
lobar bronchi and the trachea. Multiple sites of involve- 
ment were demonstrated in 30% of 31 cases (3). 
A number of different mechanisms are postulated for the 
development of endobronchial lesions in lymphoma. These 
include direct invasion from adjacent mediastinal or paren- 
chymal disease, lymphatic spread to peribronchial connec- 
tive tissues, transbronchial aspiration of tumour deposits or 
haematogenous spread. The most common mechanisms are 
thought to involve direct bronchial invasion and lymphatic 
spread (1). 
Two patterns of disease have been recognized (6). Type 1 
is characterized by the presence of diffuse submucosal 
nodules in the airways in individuals with systemic lym- 
phoma. There is usually significant pulmonary parenchy- 
ma1 involvement with associated symptoms, but signs 
referable to endobronchial obstruction or irritability are 
rare. Type 2 consists of a localized endobronchial mass in 
the central airways, without evidence of systemic lym- 
phoma but with associated regional lymph node enlarge- 
ment. This pattern has been associated in all instances with 
signs of airway obstruction such as cough or wheeze (6). 
The presenting symptoms of the disease are frequently 
non-specific, with dyspnoea, cough and wheeze the most 
common, followed by haemoptysis. Patients are rarely 
asymptomatic. 
Chest radiography shows the presence of lung collapse in 
approximately half the cases with endobronchial involve- 
ment (3), a mass or hilar shadow is noted in 20%. A nor- 
mal chest radiograph appearance is unusual. Fibre-optic 
bronchoscopy and biopsy is the definitive investigation. 
Treatment depends on the extent of involvement of the 
tumour as well as the patient’s general condition. Surgery 
alone is rarely used, with most patients now receiving 
combination chemotherapy and/or radiotherapy. 
Survival is variable; median survival in patients with 
localized disease (Type 2) is 3 years compared with 13 
months in those with generalized disease (Type 1) (3). 
The clinical importance of an endobronchial malignancy 
lies in the capacity of these lesions to produce airways 
obstruction and lung collapse. Clinically and radiologically 
it is not possible to distinguish between an endobronchial 
adenoma, carcinoma or lymphoma. In our patient the 
smoking history was highly suggestive of a primary lung 
carcinoma, with associated poor prognosis. 
It is very important to establish a diagnosis of lymphoma 
as, unlike many similarly positioned carcinomas, appropri- 
ate treatment can lead to a cure. 
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Introduction 
In 1992, the Centers for Disease Control and Prevention 
(CDC) defined idiopathic CD4’ T-lymphocytopaenia 
(ICL) as a reproducible CD4’ lymphocytopaenia 
(~300 mm- 3, in the absence of human immunodeficiency 
virus (HIV) infection or other known cause of immuno- 
deficiency (1). Ten of the 47 patients with ICL reported by 
Smith and coworkers developed opportunistic pulmonary 
infections (2), and only three cases of pulmonary tubercu- 
losis were found. On the other hand, CD4’ T-lymphocyte 
level is occasionally reported to be reduced in various 
infectious diseases including pulmonary tuberculosis (3,4). 
Case Report 
A 49-year-old man was admitted to a local hospital in 
March 1993 because of fever and increasing dyspnoea. He 
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had been well until 1 month prior to admission. He had 
no risk factors and had never taken immunosuppressive 
therapy. A chest roentgenogram on admission showed 
reticulonodular shadows (2-5 mm) distributed throughout 
both lungs with a pleural effusion in the left chest (Plate 1). 
Arterial blood gas analysis on room air showed severe 
hypoxaemia with a respiratory alkalosis (PaO,=4.64 kPa, 
PaCO,=3,31 kPa, and pH=7.50). Although antibiotics 
were administered, his hypoxaemia progressively worsened 
and he developed acute respiratory failure. Three days later, 
he was transferred to our hospital. On physical examination 
the patient appeared acutely ill, and dyspnoeic. There was 
severe lip and peripheral cyanosis. Inspiratory crackles were 
heard over both lungs. He required mechanical ventilation 
due to severe hypoxaemia. 
Laboratory studies revealed a white blood cell count of 
12200mm-3 (lymphocytes; 3%). The CD4’ cell count 
was 5lmm-’ and the CD8’ cell count 181 mm-’ (a 
CD4:CD8 ratio of 0.28) (Fig. 1). Serum immunoglobulin 
levels were normal except for a slightly low IgM level. A 
sputum smear was positive for acid-fast bacilli and subse- 
quently grew colonies (2040) of Mycobacterium tuberculo- 
sis on culture. A skin test with purified protein derivative 
was negative. Serological tests for HIV-l and HIV-2 anti- 
bodies were negative as determined by both ELISA and 
